# FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer

> **NCT04174352** · EARLY_PHASE1 · RECRUITING · sponsor: **University of Wisconsin, Madison** · enrollment: 12 (estimated)

## Conditions studied

- ERα+ Breast Cancer
- ESR1 Gene Mutation

## Interventions

- **DRUG:** Tamoxifen
- **DIAGNOSTIC_TEST:** FES PET/CT

## Key facts

- **NCT ID:** NCT04174352
- **Lead sponsor:** University of Wisconsin, Madison
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-10-20
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04174352

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04174352, "FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04174352. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*